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Abstract
Background: The expression of recombinant proteins in Escherichia coli is an important and
frequently used tool within malaria research, however, this method remains problematic. High A/
T versus C/G content and frequent lysine and arginine repeats in the Plasmodium falciparum genome
are thought to be the main reason for early termination in the mRNA translation process.
Therefore, the majority of P. falciparum derived recombinant proteins is expressed only as
truncated forms or appears as insoluble inclusion bodies within the bacterial cells.
Methods: Several domains of PfEMP1 genes obtained from different P. falciparum strains were
expressed in E. coli as GST-fusion proteins. Expression was carried out under various culture
conditions with a main focus on the time point of induction in relation to the bacterial growth stage.
Results and conclusions: When expressed in E. coli recombinant proteins derived from P.
falciparum sequences are often truncated and tend to aggregate what in turn leads to the formation
of insoluble inclusion bodies. The analysis of various factors influencing the expression revealed that
the time point of induction plays a key role in successful expression of A/T rich sequences into their
native conformation. Contrary to recommended procedures, initiation of expression at post-log
instead of mid-log growth phase generated significantly increased amounts of soluble protein of a
high quality. Furthermore, these proteins were shown to be functionally active. Other factors such
as temperature, pH, bacterial proteases or the codon optimization for E. coli had little or no effect
on the quality of the recombinant protein, nevertheless, optimizing these factors might be beneficial
for each individual construct. In conclusion, changing the timepoint of induction and conducting
expression at the post-log stage where the bacteria have entered a decelerated growth phase,
greatly facilitates and improves the expression of sequences containing rare codons.
Background
Qualitative and quantitative production of proteins in
heterologous systems is essential for the characterization
of any molecule, from determination of antigenicity,
functional and structural analysis to vaccine develop-
ment. Malaria antigens are among the most difficult
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proteins to express with in vitro methods because of their
extreme genetic codon usage. Different organisms have
been applied for the production of malaria proteins,
including  Escherichia coli [1,2], baculovirus [3,4], yeast
(Pichia pastoris and Saccharomyces cerevisiae) [5-8], trans-
genic tobacco plants [9] and transgenic mice [10]. Among
these, the E. coli expression system is the most attractive
and most frequently used, because it quickly produces
large amounts of biomass without sophisticated labora-
tory equipment and at low costs. However, the quality of
many proteins expressed in E. coli has not been satisfac-
tory. In many cases, the recombinant proteins are either
expressed as truncated forms or precipitate in insoluble
inclusion bodies in the bacterial cells. Although methods
have been developed to obtain correctly folded proteins
from these inclusion bodies, the process of refolding can-
not be successfully applied to all proteins [11,12].
Proteins expressed in insect cells using the baculovirus
system are generally correctly folded [4]. However, so far
only a few proteins have been successfully produced using
this system because many proteins turned out to be toxic
to the insect cells. In addition, the system achieves limited
yields, which makes large-scale production cost ineffec-
tive. In recent years, expression of malaria proteins in
yeast cells including P. pastoris and S. cerevisiae has been
established in several laboratories [5-8]. Recombinant
CSP, MSP-119, MSP-1-AMA-1 hybrid proteins and the
cysteine-rich inter-domain region (CIDR) of a Plasmodium
falciparum  erythrocyte membrane protein 1 (PfEMP1)
have been produced in P. pastoris for malaria vaccine stud-
ies in either primates or pre-clinical trials in humans [13].
However, for expression in P. pastoris, the codon
sequences of these antigens need to be optimized. In most
cases, sequences encoding for the amino acids of potential
glycosylation sites have to be removed. So far, this system
is the most promising one and might be the favourite
choice when it comes to the production of recombinant
malaria proteins under GMP conditions. It is nevertheless
unlikely that this system will replace E. coli as a routine
bench bioreactor due to its complicated manipulation
and relatively long cultivation times. The use of long syn-
thetic peptides (LSP) has been explored in malaria vaccine
antigen production in recent years [14,15]. The advancing
technology of peptide biosynthesis has made it possible
to produce LSP with a high degree of homogeneity and
purity. Furthermore, LSP can be designed in a way that
they contain a large number of T cell epitopes, which leads
to the generation of stronger CTL-mediated immune
responses. However, this technology also has its limita-
tions: it is still difficult to manufacture peptides that are
more than 100 amino acids in length and proteins with
multiple disulfide bonds are generally complicated to
produce.
The  P. falciparum genome is one of the most A/T-rich
genomes. Surface exposed molecules expressed by the par-
asite such as members of the PfEMP1 family are positively
charged, caused by the abundance of arginine and lysine
residues in their sequences, which complicates their
expression in heterologous systems such as E. coli. The
high content of A/T repeats in the mRNA template is a rea-
son for early translation termination and results in heter-
ogeneity of recombinant proteins. Members of the
PfEMP1 family are of great interest since they are virulence
factors that mediate adhesion of P. falciparum-infected
erythrocytes in the post-capillary microvasculature, a
process that leads to severe malaria [16]. Each PfEMP1
molecule is composed of several Duffy-binding like
domains (DBL) and CIDR domains. Both DBL and CIDR
domains have a distinct number of cysteine residues and
several lysine and arginine motifs [17]. Molecular charac-
terization, including antigenic analysis of this protein
family, relies in most cases on the successful in vitro pro-
duction of the correctly folded protein, and production of
these proteins in the native conformation remains partic-
ularly difficult.
In most studies where E. coli was used as a bioreactor, it
has been the main goal to reach as high expression levels
of the recombinant protein as possible. However, high
expression levels will not guarantee a high quality of the
final product. Efficient expression of heterologous pro-
teins in E. coli is impaired by the rarity of certain tRNAs
that are abundant in the organisms from which the heter-
ologous protein is derived [1]. When the process of
expression achieves high levels, the limited amounts of
the tRNAs will quickly be exhausted. The lack of tRNAs
will result in a drop-off of the ribosomal unit from the
mRNA template and will terminate the translation
process.
This study describes a simple method for optimizing the
cultivation conditions and especially the timepoint of
induction exemplified by the expression of several
PfEMP1 domains in E. coli. Induction at the post-log stage
of bacterial growth leads to the production of considera-
bly larger amounts of soluble protein of a higher quality
compared to standard conditions. Moreover, the method
is easily applicable in laboratories where a sophisticated
cultivation facility is not available.
Methods
Parasites
The P.falciparum parasite strains FCR3S1.2 and TM284S2
were cultured according to standard methods with 10%
AB+ Rh+ serum added to the buffered medium (RPMI sup-
plemented with Hepes, gentamycin and sodium bicarbo-
nate). Genomic DNA from these parasites was purifiedMalaria Journal 2004, 3:50 http://www.malariajournal.com/content/3/1/50
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using the EasyDNA purification kit (Invitrogen) according
to the manufacturer's protocol.
Recombinant plasmids
Plasmid constructs for the expression of the recombinant
proteins GST-DBL1α and GST-CIDR1α of
FCR3S1.2var1PfEMP1, GST-DBL1α and GST-DBL2β of
TM284S2var1PfEMP1 were generated as described earlier
[18,19].
Codon optimization and gene resynthesis
The sequence of the DBL1α domain of
FCR3S1.2var1PfEMP1 was optimized for codon adapta-
tion in E. coli. The genes were re-synthesized chemically
(GeneArt, Germany). The re-synthesized DBL1α was
amplified with oligonucleotide primers (rDBL-1 5'-ATG
GCT ACT TCC GGA GGA, rDBL-1.1 5'-TTC GAT AAG CAG
AAG AAG TAC) and cloned into the pGEX4T-1 vector as
described [20].
E. coli strain
The BL21-CodonPlus-RIL strain purchased from Strata-
gene (California, USA) was used for protein expression.
This bacterial strain has been engineered to contain a high
copy number of argenineU-, leucineW-and isoleucineY-
tRNA genes for optimal expression of heterologous pro-
teins of organisms with A/T-rich genetic sequences.
Expression of PfEMP1 domains in BL21-CodonPlus-RIL bacteria
BL21 competent cells were transformed with recombinant
pGEX4T-1 plasmids containing FCR3S1.2 DBL1α,
TM284S2 DBL1α or TM284S2 DBL2β as inserts. The
transformed bacteria were selected on LB agar plates con-
taining ampicillin (100 µg/ml). A single colony of the
transformed bacteria was inoculated in 30 ml LB medium
containing ampicillin (100 µg/ml) and chloramopheni-
col (50 µg/ml) for cultivation at 37°C overnight. Aliquots
of the culture were inoculated into one litre LB medium
with ampicillin (100 µg/ml). The cultivation was carried
out with a shaking speed of 225 rpm. The pH value and
the optical density at A600 of the cultures were monitored
systematically. Aliquots (50 ml) of each culture were
sequentially taken after the OD A600 reached 0.5 and IPTG
(isoprophyl-b-D-thiogalactopyranoside) was added to a
final concentration of 0.1 mM to induce the expression.
The expression was carried out for three hours at 37°C
and the bacteria were harvested afterwards by centrifuga-
tion at 4000 rpm for 15 minutes. The recombinant pro-
teins were purified on Glutathione-sepharose
(Amersham-Phamacia, Sweden) as described earlier
[18,19].
SDS-PAGE analysis of the recombinant proteins
To analyse the recombinant proteins, aliquots of the solu-
ble and insoluble fractions of the expressed proteins from
each purification were mixed with an equal volume of
SDS-PAGE loading buffer containing β-mercaptoethanol
and boiled at 100°C for 5 min. The denatured proteins
were resolved in 10% acrylamide gels containing 1% SDS
and visualized by staining in Coomassie brilliant blue
solution.
Binding to heparin and blood group A antigen
Purified recombinant DBL1α of FCR3S1.2 expressed with
pGEX plasmids containing either the wild-type DBL1
sequence or the codon-optimized sequence was further
passed through a heparin-HiTrap column (Amersham-
Phamacia Biotech, Sweden). After washing with PBS
tween-20 buffer, the bound protein was released from the
column with 2M NaCl and dialyzed immediately against
cold PBS. Aliquots of the eluted proteins were subjected to
SDS-PAGE.
The binding of recombinant DBL1α of FCR3S1.2 to blood
group A antigen was studied using a solid phase assay sys-
tem as described earlier [20].
Results and discussion
The expression of three different DBL-domains and one
CIDR-domain as recombinant proteins in E. coli was
induced either at an OD A600 of 0.6, which is commonly
recommended or at an OD A600 higher than 2.0. SDS-
PAGE analysis (Figure 1) shows that most of the recom-
binant proteins of the cultures induced at a low OD A600
(Figure 1, lane 1, 3, 5, 7) were truncated at the C-terminal
end displaying multiple bands of different molecular
weights, while the intact protein represents only a small
fraction of the overall protein yield. In contrast, if the
expression was induced at a higher OD A600 (Figure 1, lane
2, 4, 6, 8), the dominant fraction of the protein was found
to be the intact form, which proved to be true for all four
domains tested although derived from different PfEMP1s.
In bacterial cultures, the growth will be at log phase
between an OD A600 of 0.3 and 1.5. During the log phase,
the number of bacteria in the culture doubles approxi-
mately every 20 minutes. Afterwards, the proliferation rate
slows down due to the lack of nutrients. If the induction
is initiated while the bacteria grow in log phase, the bac-
terial translation machinery will be highly active and the
expression of the recombinant protein follows this pro-
file, because once turned on, the promoter controlling the
heterologous sequence on the vector does not underlie
further control mechanisms. During expression, the rare
codons of arginine, leucine, isoleucine and proline fre-
quently found in PfEMP1 sequences will inhibit the trans-
lation process, most likely caused by the exhaustion of the
tRNAs for these amino acids. It has been reported that the
rare codons of arginine and proline are likely to cause
frameshifts and with that undesired products in bacterialMalaria Journal 2004, 3:50 http://www.malariajournal.com/content/3/1/50
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expression system [21-23]. The data reported here indi-
cate that these problems mainly occur during the high-
level expression stage, since proteins expressed at post-log
growth stage are much less truncated.
Enzymatic digestion of heterologous proteins in E. coli is
thought to be an additional reason for product heteroge-
neity of recombinant proteins [24]. The experiments of
this study could not confirm degradation by bacterial pro-
teases as one of the major causes, since the use of a pro-
tease inhibitor cocktail in the purification protocol did
not affect the pattern of the expressed products (data not
shown). In addition, expression was carried out using a
BL21 Codon Plus bacterial strain (Stratagene) that is defi-
cient in the OmpT and Lon bacterial proteases.
We have previously found that a large proportion of the
recombinant proteins remain in the insoluble fraction
whereas only small amounts appear in the soluble frac-
tion (Figure 2 and data not shown) if expression is initi-
ated at an OD A600 of 0.6. To check whether the bacterial
growth status at the induction timepoint has any effect on
protein solubility, induction of expression was carried out
on aliquots of the same bacterial stock culture at different
bacterial densities (OD A600 value). Both soluble and
insoluble fractions of the same culture were compared.
The results (Figure 2A–C) clearly show that the majority of
the three recombinant proteins remain in the insoluble
fraction when the expression was induced at an OD A600
below 2.0. If, on the other hand, the induction is initiated
at an OD A600 greater than 2.0, almost the total amount of
the recombinant proteins appears in the soluble fraction.
The solubility of a protein correlates with its correct struc-
ture that is formed during a post-translational folding
process. Freshly synthesized polypeptides remain in a
stage of intermediate form in the bacterial cytoplasma.
After several enzymatic and biochemical processing steps,
the peptides are folded into their functional form [24].
However, if proteins are folded incorrectly, they tend to
accumulate as aggregates in the bacterial cell and, in order
to avoid toxic effects on the host system, the bacteria store
these aggregates in confined structures referred to as inclu-
sion bodies.
Formation and accumulation of heterologous proteins as
inclusion bodies is a common problem in protein expres-
sion. The exact mechanism of this process is still not
understood. It has been suggested that factors such as cul-
ture pH, temperature and protein amino acid composi-
tion might affect the solubility of a recombinant protein
[24]. The data reported here indicate that the expression
Comparison of recombinant DBL, CIDR proteins expressed at mid-or post-log phase Figure 1
Comparison of recombinant DBL, CIDR proteins expressed at mid-or post-log phase. Expression of GST-DBL1α and GST-
CIDR1α of FCR3S1.2, GST-DBL1α and GST-DBL2β of TM284S2 was induced when the bacterial growth was at mid-log 
respectively post-log stages. The purified recombinant proteins were analysed in SDS-PAGE. Results presented in lane 1, 3, 5 
and 7 are proteins purified from cultures where expressions was initiated at mid-log phase, while lane 2, 4, 6 and 8 show pro-
teins after induction at post-log phase. The intact fraction of each expressed protein is marked with an arrow. Proteins were in 
addition verified by Western-Blot both with anti-GST-and anti-DBL1-antibodies [26].
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Impact of bacterial growth stages on protein solubility Figure 2
Impact of bacterial growth stages on protein solubility. The expression of the three recombinant proteins was induced at vari-
ous timepoints chosen gradually from low OD A600 to higher OD A600. The comparison of the soluble and insoluble fractions 
of the recombinant proteins revealed that after initiation of expression at an OD A600 of greater than 2.0, the recombinant 
proteins are found almost completely in the soluble fraction. The amount of each protein loaded is not proportional to the size 
of the cultivation.
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speed and, with that, the subsequent folding process is the
most important factor. Protein expression at the post-log
phase resulted in high amounts of soluble protein, which
indicates that at this stage the low bacterial growth rate
implicates a biosynthesis process that is kept at low speed.
The slow synthesis process will allow the protein process-
ing machinery to efficiently assemble the freshly synthe-
sized peptides into the correct structure. Correctly folded
proteins are most likely to stay in the soluble form pro-
vided that the molecule does not contain large numbers of
hydrophobic residues.
Although we found that the pH value of the growing cul-
ture is influenced by the amino acid composition of the
expressed polypeptide, keeping a stable pH value in the
bacterial culture does not affect the protein solubility
(data not shown) and, therefore, has little influence on
the quality of the expressed protein. However, tempera-
ture is an important factor to consider. Keeping the culture
at 16°C before and after induction slightly improves the
protein quality (data not shown), but, on the other hand,
slows down bacterial growth considerably and therefore
minimizes the final yield of the recombinant protein.
Binding to heparin Figure 3
Binding to heparin. Recombinant GST-DBL1α of FCR3S1.2 was purified from cultures with induction at mid-log (lane 1) and 
post-log stage (lane 2) and bound to heparin. Protein expressed by bacteria at post-log stage showed considerably higher affin-
ity to heparin.
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It has been reported that codon-optimized sequences for
the use in E. coli will improve expression quality. Here we
show that C/G versus A/T contents of the heterologous
gene sequence are not among the most important factors
that determine the quality of the recombinant protein.
The expression of GST-DBL1α of FCR3S1.3 (Figure 2A)
optimized for expression in E. coli shows a very similar
expression pattern compared to those ones of GST-DBL1α
and GST-DBL2β of TM284S2 which were expressed using
the wildtype P. falciparum sequences (Figure 2B,C). This
indicates that sequence composition is not always a deter-
minant factor for expression quality.
We have previously found that the DBL1α domain of
FCR3S1.2var1 PfEMP1 binds to the human erythrocyte
surface through heparan sulfate [20,25]. Further, the
recombinant GST-DBL1α of FCR3S1.2 protein can be
purified through binding to heparin-sepharose. In this
study, the same amount of GST-DBL1α purified from cul-
tures of expression started at an OD A600 of 0.6 and greater
than 2.0 was tested for its ability to bind to heparin.
Although the truncated forms of the DBL1 display bind-
ing to heparin due to the presence of heparin-binding
motifs in these peptides, there is a remarkable difference
in terms of binding affinity between the proteins
expressed at different bacterial densities as shown in Fig-
ure 3. Proteins expressed at a high OD A600 are not only
more intact and more soluble, but also display higher
affinity to heparin.
To further demonstrate functionality of the proteins
expressed at high OD A600 the DBL1α of FCR3S1.2 was
subjected to a blood group A binding assay, which con-
firmed the specific interaction between the DBL1α and
the blood group A antigen (data not shown).
The expression of P. falciparum derived proteins, especially
membrane-bound proteins is still a great challenge due to
the high content of amino acids encoded by rare codons
in the P. falciparum genome. The method reported here
presents an easily applicable tool to express sequences
containing rare codons. The key factor for the expression
of such proteins is to decelerate the translation machinery
inside the bacteria. Low expression speed will not only
allow the ribosomal unit to smoothly pass through the
mRNA templates and synthesize full-length polypeptide
chains, but also enable the proteins to slowly transfer
from the unstable intermediate phase to the correctly
folded phase. The described expression approach will
result in a final product that is soluble, intact and func-
tional, nevertheless, additional factors might influence
the expression and need to be optimized for each individ-
ual construct.
The expression of eukaryotic genes in E. coli is one of the
most frequently used tools in modern science. Numerous
approaches have aimed at achieving the highest possible
level of expression by having a maximum amount of pro-
tein expressed per bacterial cell. Our studies suggest on the
contrary that increasing the number of bacterial cells in
the culture while at the same time keeping the expression
process at a low profile, might considerably improve the
quality and quantity of the protein. That way, high level
expression can simply be achieved by increasing the bac-
terial density of a culture, whereby problems in form of
truncated or insoluble protein factions are almost com-
pletely eliminated.
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